AbbVie Inc. (ABBV) Price and Market Data
Explore real-time AbbVie Inc. (ABBV) price, market cap, trading volume, and price changes. View the live price chart and key reference data.
AbbVie Inc. price chart+5.37%1M
Next ABBV earnings
February 4, 2027in 88 days
Q4 2026 · Time not confirmed · Estimated · 3 more in the next 12 months
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Reference
- Exchange
- NYSE
- Sector
- Drug Manufacturers - General
- Employees
- 57,000
- Listed
- 12/10/2012
- Market cap
- $514.924B
- Shares outstanding
- 1,768,169,012
- Currency
- USD
- Website
- https://www.abbvie.com